교수진 및 연구실 소개SAIHST에는 기초의학, 임상의학, 자연과학, 약학, 공학, 경영대학 등 Health Science와 관련된 다양한 분야를 전공한 교수진이 참여하고 있습니다.
미래의과학을 선도할 역량있는 교수의 참여를 기다립니다.
| 연구실소개 |
Lab of mesenchymal stem cells andextracellular vesicles for rare /장윤실 교수 E-mail : cys.chang@samsung.com Homepage : 참여학과 : 융합의과학과, 의료기기산업학과, 임상연구설계평가학과 인쇄하기 |
|
Lab of mesenchymal stem cells and extracellular vesicles for rare or incurable disorders (of neonate)
■ Introduction The major subject of study in our laboratory is translational research involving mesenchymal stem cells (MSCs) and/or MSC-derived extracellular vesicles (MSC-EVs), including exosomes(MSC-exo), for rare or incurable disorders, especially in newborn infants. ■ Research field Our preclinical studies have demonstrated the beneficial effects of MSCs or MSC-exo on various animal models, including those of bronchopulmonary dysplasia (BPD, a developmental and chronic lung disease affecting premature infants), intraventricular hemorrhage (IVH, which causes severe neurologic dysfunction in extremely preterm infants), hypoxic-ischemic encephalopathy (HIE, a perinatal brain injury due to asphyxia in newborn infants), bacterial meningitis, and acute respiratory distress syndrome (ARDS). Moreover, in the first-in-human clinical trials that have been done or are underway, Safety and efficacy of MSC transplantation in extremely premature infants for BPD intratracheally and for IVH and HIE intracerebroventricularly has been assessed. To improve the shortcomings of existing MSC therapies, we are focusing on improving the efficacy of the methods and mechanisms by controlling the stem cell micro-culture environment. We are also continuing the development of stem cell-derived EV (exo) treatments, using EVs secreted from stem cells. To develop the latter as a clinical-grade drug, we are conducting a study in collaboration with the GMP of Samsung Medical Center and are investigating the pharmacological efficacy and mechanism through proteomic genome analysis. We are also acquiring diagnostic evidence and developing customized personalized treatments through biometric analyses of genomes and proteomic substances in clinical specimens, including the meconium, gastric aspirate, lung aspirate, and umbilical cord blood. These specimens are being non-invasively collected from newborns in collaboration with colleagues at Samsung Seoul Hospital Biobank and the Department of Basic Science, Sungkyunkwan University College of Medicine. ■ Members( PIs & sub-PIs ) Won Soon Park M.D.,Ph.D. Yun Sil Chang M.D.,Ph.D. Se In Sung M.D.,Ph.D. So Yoon Ahn M.D.,Ph.D. Dong Kyung Sung, Ph.D. Young Eun Kim Ph.D. |